FDA warns about sexual enhancement supplement
This article was originally published in The Tan Sheet
Executive Summary
The agency warns consumers Aug. 25 about TimeOut Capsules because they contain an undeclared ingredient. Hydroxythiohomosildenafil is similar to sildenafil, the FDA-approved ingredient in Pfizer's prescription Viagra, and may interact with nitrates to cause unsafe drops in blood pressure. "TimeOut is labeled as '100% natural' and consumers may mistakenly assume the product is harmless and poses no health risk," FDA said. The TimeOut warning is the latest in what has become a stready stream of alerts and recall announcements for so-called weight-loss and male enhancement supplements found to contain undeclared drugs (1"The Tan Sheet" Aug. 23, 2010, In Brief)
You may also be interested in...
Weight-loss, male enhancement drugs recalled
The maker of Mr. Magic Male Enhancer from Don Wands sexual enhancement product voluntarily launches a recall after FDA determined the presence of undeclared ingredients. Glow Industries said Aug. 18 it recalled Mr. Magic because it contains hydroxythiohomosildenafil and sulfoaildenafil, analogues of sildenafil, an Rx ingredient for treatment of erectile dysfunction that may react unsafely with nitrates. Separately on Aug. 19, J&H Besta expanded a previous recall of its Slim-30 Herb Supplement weight-loss product, the subject of a recent FDA consumer advisory, because it contains undeclared desmethyl sibutramine, similar in structure to the appetite suppressant drug sibutramine (1"The Tan Sheet" July 26, 2010, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.